1. Introduction
A substantial and consistent amount of information has accumulated in recent decades regarding the beneficial effects of vitamin D (VD) during the perinatal period. VD exerts its biological activity mainly at the transcriptional level, through the binding of its active metabolite, calcitriol, to the vitamin D receptor (VDR). The human placenta is a target and a source of calcitriol, as it expresses both the VDR and the vitamin D-activating cytochrome CYP27B1. Aside from its well-known calciotropic properties, the biological effects of VD during pregnancy can be categorized into four main domains. Firstly, VD exhibits anti-inflammatory properties by downregulating systemic and placental inflammatory factors, thereby maintaining a balanced immune response by limiting an exacerbation during inflammatory events [
1,
2,
3]. Secondly, VD boosts the innate immune response by inducing antimicrobial peptides, aiding in defense against viral and bacterial invasions [
3,
4,
5]. Thirdly, VD helps regulate the synthesis of placental steroid and protein hormones, contributing to a healthy pregnancy [
6,
7,
8]. Lastly, VD regulates blood pressure, a crucial factor for pregnant women. In this regard, it is well established that calcitriol downregulates renin gene expression, as demonstrated in renal cells both
in vitro and
in vivo [
9]. As a result, calcitriol inhibits the renin–angiotensin system (RAS), which is tightly involved in blood pressure modulation and electrolyte and volume homeostasis [
10,
11]. The RAS mediates its effects by generating angiotensin II (Ang II), a potent vasoconstrictor peptide. Ang II is synthesized after two sequential cleavage reactions, the first one upon angiotensinogen, catalyzed by renin, and the second one upon the resulting product, angiotensin I (Ang I), by the angiotensin-converting enzyme (ACE1). Since renin is the rate-limiting enzyme in Ang II synthesis, factors that modify its transcriptional regulation and secretion are of clinical importance in hypertensive disorders. In this context, and consistently with the inhibition of renin by calcitriol, pre-clinical, clinical and epidemiological studies have shown a negative association between calcitriol and blood pressure, as well as a reduction in blood pressure after patients treatment with calcitriol, its analogs or its precursor cholecalciferol [
9,
12,
13,
14,
15,
16,
17]. Similarly, a negative correlation between calcitriol cord blood levels and maternal blood pressure has been described in a cohort of pregnant women affected by urinary tract infections [
18], strongly suggesting that placental calcitriol is involved in lowering maternal blood pressure. Blood pressure during pregnancy must be closely monitored since hypertensive disorders of pregnancy can significantly increase perinatal morbidity and mortality [
19]. In this sense, the natural counter-regulatory mechanism of RAS activation is represented by ACE2, which hydrolyzes Ang I and Ang II into Ang-(1-9) and Ang-(1-7), respectively [
20]. Particularly, Ang-(1-7) acts as a vasodilator, anti-hypertensive, antioxidant and anti-inflammatory peptide [
20]. The human placenta expresses all components of the RAS [
21,
22], being ACE2 mainly expressed in the syncytiotrophoblast layer [
23]. Interestingly, ACE2 also acts as a receptor for SARS-CoV-2, the causal agent of COVID-19 disease, which produced the recent health contingency pandemic [
24]. Accordingly, SARS-CoV-2 viral particles have been mainly localized in syncytiotrophoblast cells (STB) at the materno-fetal interface of the placenta [
24,
25]. In the aftermath, among the most vulnerable groups, the impact of COVID-19 was particularly significant among pregnant women, given that this disease was associated with increased risk of maternal death, cardiovascular disorders, obstetric hemorrhage, hypertension, and preeclampsia [
26]. The mechanism of SARS-CoV-2 infection starts with the binding of the coronavirus spike proteins (S) receptor binding domain (RBD) to host cells membrane ACE2, followed by S cleavage by the transmembrane serine protease TMPRSS2. This process allows the viral envelope to fuse with the host cell membrane, after which the viral RNA is released into the cell for translation into structural and accessory viral proteins needed for genome replication. Thus, both ACE2 and TMPRSS2 are fundamental for the SARS-CoV-2 infection, representing potential therapeutic targets [
27]. Notably, a significant amount of information has accumulated supporting a protective role of VD against COVID-19 severity and mortality [
28,
29], which is thought to be mediated through the downregulation of proinflammatory cytokines, the production of antiviral proteins and several other mechanisms [
30,
31,
32]. However, there are contrasting results in the literature regarding the effects of calcitriol on
ACE and
TMPRSS2 expression in different tissues and conditions (
Supplementary Table S1). At the same time, minimal information is available on the influence of VD in the components of RAS at the placental level. Therefore, in this study, we aimed to explore how calcitriol transcriptionally regulates RAS-related factors in cultured human trophoblast from term and first trimester placentas, to gain a deeper understanding on the potential role of placental VD in regulating COVID-19 susceptibility and maternal blood pressure during pregnancy.
3. Discussion
It is a well-known fact that SARS-CoV-2 uses ACE2 as a receptor in host cells and that TMPRSS2 primes S protein to facilitate viral RNA entry into the cells [
27], highlighting the importance of these proteins in cell infection and COVID-19 therapeutic opportunities. The human placenta expresses
ACE2 and
TMPRSS2, whose levels vary depending on cell type and pregnancy trimester [
40]. While conflicting information on the transmission of SARS-CoV-2 from mother to child exists, it is now well recognized that this virus can vertically infect the fetus by bypassing placental barriers, albeit at a low rate [
41,
42]. Importantly, STB is highly susceptible to SARS-CoV-2, representing the primary target of infection among placental cells, most probably due to the high levels of
ACE2 and
TMPRSS2; thus, supporting SARS-CoV-2 efficient entry and replication [
41,
43,
44]. Accordingly, ACE2 knockdown in cultured placental cells abolished viral infection, drastically decreasing the SARS-CoV-2 genome presence in supernatants and cell lysates [
43]. Similarly, the SARS-CoV-2 infection of STB cells was prevented by using anti-ACE2 antibodies [
44]. This background strongly supports ACE2 and TMPRSS2-targeting as a strategy to prevent placental infection and vertical transmission of the virus. In the present study, we show that calcitriol and its precursor calcidiol significantly downregulated
ACE2 gene expression both in primary STB and HTR8 cell cultures, firmly suggesting that intracrine and exogenous calcitriol can diminish the risk of viral entry into trophoblast cells, placental SARS-CoV-2 infection, and consequently, fetal infection. Our results are supported by an
in silico analysis identifying the VDR as a putative repressor of
ACE2 gene expression [
45]. Moreover, calcitriol also diminished
TMPRSS2 gene expression in first trimester HTR8 cells. Notably, in
in vitro and experimental animal studies,
TMPRSS2 KO contributed to reduced viral lung replication, low proinflammatory reaction, and mild lung pathology [
46], while the functional inhibition of this protease blocked SARS-CoV-2 entry [
27], demonstrating a positive defensive outcome through the suppression of TMPRSS2. Interestingly, TMPRSS2 is an androgen-stimulated gene, containing multiple androgen response elements upstream of its gene transcription start site [
47,
48], partially explaining the male bias in susceptibility to severe COVID-19 disease and mortality [
49,
50]. Accordingly, TMPRSS2 expression has been found significantly higher in placentas from male fetus compared to those from female [
51]. Thus, its downregulation by calcitriol might have special positive implications for male offspring vulnerability, deserving further studies.
If our results are replicated in other cell types, they could contribute to explain the acknowledged preventive role of VD sufficiency upon COVID-19 infection and severity [
28,
29]. However, we did not anticipate the outcomes on
TMPRSS2 and
ACE2 gene expression, given the contrasting information reported in different tissues and conditions, with ACE2 being either upregulated or downregulated by VD derivatives (
Supplementary Table S1). Nevertheless, our findings complement other studies postulating additional mechanisms by which active VD metabolites can impede viral entry. For instance, computational and functional analyses have demonstrated the potential for VD derivatives to physically bind ACE2 and TMPRSS2, thereby affecting their ability to recognize and prime the SARS-Cov2 S protein [
52,
53]. Similarly, molecular simulations have shown the feasibility of the bonding between VD derivatives and the spike protein, stabilizing it in the locked conformation, thus inhibiting its interaction with the host receptor [
53,
54]. Moreover, VD hydroxymetabolites have shown the potential to inhibit SARS-CoV-2 infection by restricting its replication cycle, through targeting SARS-CoV-2 replication enzymes [
55]. Altogether, this information identifies VD active compounds as potential natural therapeutic agents for preventing placental SARS-CoV-2 infection.
On the other hand, it is well established that VD limits RAS activity by inhibiting renin expression [
9,
10,
11]. Renin is released by the kidneys into the bloodstream when blood pressure drops. Then, renin catalytically cleaves circulating angiotensinogen to form Ang I, which ACE1 converts into Ang II, a potent vasoconstricting peptide hormone that efficiently raises blood pressure. Notably, experimental studies in mice have shown that renin from placental origin is released into maternal circulation and can cause hypertension [
56]. In addition, it has been reported that the risk of developing hypertensive disorders of pregnancy in patients who tested positive for COVID-19 is over 70% higher than in those who did not [
57], which is in line with the described association between severe COVID-19 and hypertension [
58]. Therefore, an equilibrated placental RAS regulation, emphasizing renin expression, is crucial for an adequate pregnancy outcome, especially under the threat of COVID-19 infection. In this regard, we found in this study that REN gene expression was significantly downregulated by calcitriol in STBs and EVT cells. Both types of placental cells play distinct and important roles in the placenta, STBs primarily contributing to hormonogenesis, nutrient exchange, and immune regulation, while EVTs are involved in establishing the placental-uterine interface and maternal spiral arteries remodeling. The fact that calcitriol downregulated placental
REN gene expression might be associated with its capacity to lower maternal blood pressure, which is in line with previous findings from our laboratory showing a negative correlation between cord blood calcitriol and maternal systolic and diastolic blood pressure in a cohort of patients with urinary tract infections [
18]. While hypertension is associated with maternal mortality and perinatal morbidity, the causative mechanisms are not yet fully clarified. However, several conditions have been associated with this disorder, including placental ischemia, abnormal EVT invasion of spiral arteries, endothelial dysfunction, and increased production of placental vasoconstrictor factors [
59]. Additional risk factors are placental and systemic inflammation, characterized by exacerbated inflammatory cytokines production [
60]. Notably, the cytokine storm is a characteristic feature of COVID-19 infection, while placental inflammation and malperfusion have been reported in SARS-CoV-2-infected placentas [
61]. Thus, the ability of calcitriol to restrain inflammation by downregulating placental inflammatory cytokines production [
2] and to inhibit REN gene expression in trophoblast cells, as shown herein, may help to regulate blood pressure both under normal and COVID-19 infection conditions. Our results concur with Chen Chun-yan et al., who described that the treatment with calcitriol or calcidiol significantly reduced REN gene expression in cultured decidual epithelial cells [
62].
An imbalance in RAS and its ACE1/ACE2 components has been proposed as a driver of COVID-19 pathobiology [
38,
63]. Indeed, SARS-CoV-2 infection causes inhibition of ACE2 in infected cells, increasing Ang II signaling [
64]. In our study, the ratio
ACE1/ACE2 was significantly reduced by calcitriol in placental cells, showing different trends depending on the hormone concentration. This result could reflect a positive outcome
in vivo, given that a high ACE1/ACE2 ratio has been recognized as a critical predictor for COVID-19 severity [
63]. Although calcitriol reduced this ratio in both cell types, the observed concentration-dependent differences might be consequential to the basal expression levels of both enzymes in each cell type, being ACE2 increased in STBs as compared to HTR8 cells, while ACE1 was within a similar expression rate. Also, the robust calcitriol-dependent inhibitory effect upon ACE1 in STBs compared to HTR8 might play a role, given that EVT cells required higher calcitriol concentrations for ACE1 downregulation compared to STBs. Based on the baseline expression levels of RAS components, it appears that STBs play a more preponderant role in the RAS placental system than EVT cells.
Previously, as an extrapolation of VD inhibiting the RAS, it had been postulated that VD restricts SARS-CoV-2 viral entry through the downregulation of ACE2 expression [
32,
65]. However, contradictory and limited information exists on ACE2 transcriptional regulation by calcitriol (
Supplementary Table S1). At the same time, there is no information on the effects of VD derivatives on
ACE2 and other RAS components’ expression at the feto-maternal unit, aside from one study regarding
REN in decidua [
62]. Thus, to our knowledge, this is the first report showing the transcriptional regulation of placental RAS components by VD natural derivatives in two different cell types.
While ACE2 helps to regulate blood pressure by shifting the balance towards vasodilators and anti-hypertensive factors such as Ang-(1-7), it also facilitates SARS-Cov-2 entry by binding to the viral S protein. These facts highlight the role of ACE2 as a double-edged sword in the context of COVID-19. In this scenario, our results showing ACE2 and TMPRSS2 downregulation by calcitriol suggest the reduction of the entry gate of SARS-CoV-2 to the placenta. At the same time, the inhibition of ACE1 and REN may account for blood pressure attenuation. The latter is supported by the reduced ACE1/ACE2 ratio in calcitriol-treated cells observed in this study. This outcome could translate into therapeutic opportunities for the prevention and mitigating effects of COVID-19.
Among the limitations of our study, the lack of RAS components protein analysis, Ang(1-7) quantification, and
in vivo experiments, remain areas that warrant further exploration. In addition, since the RAS placental system is involved in placentation by participating in spiral artery remodeling, trophoblast invasion and placental angiogenesis [
22], further studies are needed to understand the impact of VD as a modulator factor of placental RAS.
In summary, our results support the beneficial effect of VD sufficiency during pregnancy as a protective factor against hypertensive disorders and, possibly, COVID-19 vertical transmission.